Smoking Just 1 Cigarette a Day Can Significantly Damage Your Health, Study Finds

iStock
iStock

Cutting back on smoking is a noble goal, but simply decreasing the amount of cigarettes you smoke—rather than quitting entirely—isn't as helpful as you might think when it comes to the health risks of tobacco use. ABC News reports that new research published in the BMJ finds that smoking just one cigarette a day still increases the risks of heart disease and stroke significantly.

Led by researchers from University College London and King’s College London, the study found that compared to not smoking at all, smoking one cigarette a day resulted in a 46 percent greater risk of heart disease and a 25 percent greater risk of stroke for men, and for women, a 57 percent greater risk of heart disease and 31 percent greater risk of stroke. Even if a person cuts down from smoking 20 cigarettes a day to one, the study found, the risks of developing heart disease and stroke are only halved—not reduced by 95 percent, as would be proportional. (Previous research has found that lung cancer risk, by contrast, decreases proportionally depending on the number of cigarettes smoked per day.)

The researchers examined 141 previous studies, reported in 55 publications, analyzing the risks of heart disease and stroke among men and women who smoked. The studies each examined risks of light smoking (defined as one to five cigarettes a day) and the risks associated with heavy smoking, or 20 cigarettes per day. The researchers adjusted for whether the studies considered factors like age, cholesterol, and blood pressure, all of which can also impact a person’s risk of heart disease and stroke.

The findings show that any amount of smoking carries high risks. While one cigarette a day might seem like nothing to a heavy smoker, its impacts on the body are significant, and shouldn't be underestimated, either by smokers or by their doctors.

[h/t ABC News]

FDA Recalls Thyroid Medications Due to Contamination Risk

iStock
iStock

Hypothyroid medications manufactured by Westminster Pharmaceuticals have been recalled after it was discovered that one of the company’s Chinese suppliers failed to meet U.S. Food and Drug Administration (FDA) standards, CNN reports.

The oral tablets contain levothyroxine (LT4) and liothyronine (LT3), which are both synthetic hormones used to treat thyroid conditions.

The medicine was recalled as a precaution after it was discovered during a 2017 FDA inspection that the Chinese supplier in question, Sichuan Friendly Pharmaceutical Co., was not practicing good manufacturing practices.

However, patients with serious thyroid conditions shouldn’t throw out their pills just yet. No adverse effects from the medication have been reported, and the risk of not taking the medication outweighs the risk of taking a recalled pill.

According to the FDA, “Because these products may be used in the treatment of serious medical conditions, patients taking the recalled medicines should continue taking their medicine until they have a replacement product.”

For more information on the specific lots and products in question, visit the FDA’s website.

[h/t CNN]

The First Generic EpiPen Just Received FDA Approval

iStock
iStock

For people with severe allergies, having an EpiPen on hand could mean the difference between life and death. But that safety net comes at a high price: In the past decade, the cost of the brand-name drug has risen by more than 400 percent, with a set of two pens selling for $600. Now, CNBC reports that patients can finally get the treatment they need for a more reasonable amount of cash: The FDA has approved a generic version of Mylan's EpiPen, making it the first direct generic competitor to the brand-name medication.

Teva Pharmaceutical's versions of both the EpiPen and EpiPen Jr. will work like the originals, with an injector delivering epinephrine, a chemical that opens the airways, into the bloodstream of someone suffering an allergic reaction. Similar generics have been made commercially available in the past: In 2016, Mylan introduced a cheaper version of its own product at $300 for a two-pack, and in 2017 CVS started selling an EpiPen alternative for $110. Teva's drug is different, though. It's a direct generic copy of the EpiPen, which means pharmacists will be free to offer it to patients who have been prescribed Mylan's product. A price hasn't been announced, but Teva's EpiPen could end up being significantly cheaper than Mylan's generic EpiPen, which could in turn bring down prices of the injector drug across the board.

The exorbitant price of the EpiPen has hit patients hard in recent years. Some EMTs have even started loading epinephrine into syringes manually rather than paying for the drug-injector combo. Though the drug itself isn't protected by a patent, the design of the EpiPen device is difficult for competing pharmaceutical companies to replicate, which has allowed Mylan to charge whatever it can for the product.

In 2017, the FDA tweaked its guidelines to make it easier for generic EpiPen competitors to receive market approval, even if the design of the new injector differed slightly from the original. With the approval of Teva's auto-injector made official, more EpiPen generics could soon start appearing behind pharmacy counters.

[h/t CNBC]

SECTIONS

arrow
LIVE SMARTER
More from mental floss studios